Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
137 hedge funds and large institutions have $394M invested in Achillion Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 13 closing their positions.
144% more call options, than puts
Call options by funds: $632K | Put options by funds: $259K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
28% more capital invested
Capital invested by funds: $307M → $394M (+$86.9M)
10% more funds holding
Funds holding: 124 → 137 (+13)
3% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$5.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.35M |
| 3 |
NC
Nexthera Capital
New York
|
+$4.72M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.13M |
| 5 |
Millennium Management
New York
|
+$3.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.46M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.92M |
| 3 |
AC
Armistice Capital
New York
|
-$5.96M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.62M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.57M |
ACHN Hedge Fund Activity: Q3 2018 in Review
137 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2018, worth a combined $394M — up 28% from $307M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ACHN positions and 13 closed out — a net gain of 13 holders — while 41 added to existing stakes and 40 trimmed.
The largest buyer was MAK Capital One, opening a new position worth an estimated $5.8M. The largest seller was Great Point Partners, exiting entirely with an estimated $8.46M sold.
- 137 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2018, up from 124 in Q2 2018.
- Funds reported $394M of Achillion Pharmaceuticals stock for Q3 2018, up 28% quarter-over-quarter.
- 26 funds opened new Achillion Pharmaceuticals positions in Q3 2018 and 13 closed out, a net change of +13 holders.
- The largest Achillion Pharmaceuticals buyer in Q3 2018 was MAK Capital One, an estimated $5.8M added.
- The largest Achillion Pharmaceuticals seller in Q3 2018 was Great Point Partners, an estimated $8.46M sold.
Based on aggregated 13F filings for Q3 2018.